Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06065124

Bariatric Surgery Evaluation and Assessment of Treatment Efficacy - Intervention Trial

The goal of this clinical trial is to evaluate if a bariatric surgery strategy will improve clinical endpoints, cardiac parameters and functional status in patients with obesity (with BMI 32-40 kg/m2) and symptomatic HF with preserved or mildly reduced LVEF in combination with AF, as compared to standard of care. Patients will be randomized to either the Intervention group receiving bariatric surgery including an intensive pre- and postoperative treatment scheme or to the control group receiving standard of care.

Recruiting

Interested in participating?

Request Info

Key information

Age range

45 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rijnstate Hospital, Arnhem, Gelderland, Netherlands

Loading trial locations.

About this study

The primary objective is to study the effect of a bariatric surgery strategy on the hierarchical occurrence of: 1) all-cause mortality within 2 years, 2) emergency room visit or hospitalization for HF within 2 years, 3) recurrent ECG-documented AF within 2 years, 4) decrease of ≥30gr of left ventricular (LV) mass on transthoracic echocardiography, and 5) improvement of ≥5 points on the Kansas City Cardiomyopathy Questionnaire (KCCQ).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signs and symptoms of HF according to the Europeans Society of Cardiology guideline;
  • Left ventricular ejection fraction ≥40%;
  • HFA-PEFF score ≥5 or HFA-PEFF score 2-4 in combination with positive stress test;
  • Between 45 and 70 years of age;
  • BMI 32-40 kg/m2;
  • Paroxysmal or persistent AF with a rhythm control strategy;
  • Willing to undergo both treatment strategies;
  • Written informed consent.

Exclusion criteria

  • BMI ≥40 kg/m2;
  • BMI <32 kg/m2;
  • Patients unwilling or unable to sign informed consent;
  • More than moderate mitral valve regurgitation/aortic valve regurgitation;
  • More than mild mitral valve stenosis/aortic valve stenosis;
  • Inadequate echocardiographic window for the assessment of LV mass index and/or the echocardiographic criteria needed for the HFA-PEFF score;
  • History of myocardial infarction, myocarditis, any invasive cardiac intervention (e.g. surgery, percutaneous coronary intervention, ablation) or stroke, <3 months before inclusion;
  • Scheduled for AF ablation;
  • Complex congenital heart disease;
  • Negative treatment advise from a specialized psychiatrist due to non-stabilized psychotic disorders, severe depression and/or personality disorders;
  • Patients unable to care for themselves or who are unable adapt to inherent lifestyle changes following bariatric surgery;
  • Any medical condition that limits life span <2 years;
  • Diseases requiring long term use of anti-inflammatory treatments;
  • The use of medication associated with substantial effects (>5 kg) on body weight.

Treatment and study plan

Bariatric surgery strategy

Procedure

Bariatric surgery including an intensive pre- and postoperative treatment scheme

Primary outcomes

  1. Hierarchical endpoint

    Time frame: 2 years

    The hierarchical occurrence of: 1) All-cause mortality; 2) Emergency room visit or hospitalization for HF; 3) Recurrent ECG-documented AF; 4) Decrease of ≥30gr of LV mass on transthoracic echocardiography; 5) Improvement of ≥5 points on the Kansas City Cardiomyopathy Questionnaire (Scores are transformed to a range of 0-100, in which higher scores reflect better health status)

Secondary outcomes

  1. All-cause mortality

    Time frame: 2 years

    All-cause mortality

  2. Emergency room visit or hospitalization for HF

    Time frame: 2 years

    Emergency room visit or hospitalization for HF

  3. Rate of recurrent AF

    Time frame: 2 years

    Recurrent AF documented on ECG

  4. Decrease of left ventricular mass

    Time frame: 2 years

    Decrease of ≥30gr of LV mass measured by transthoracic echocardiography

  5. Kansas City Cardiomyopathy Questionnaire improvement

    Time frame: 2 years

    Improvement of ≥5 points on the Kansas City Cardiomyopathy Questionnaire (scores are transformed to a range of 0-100, in which higher scores reflect better health status)

Other outcomes

  1. Weight reduction

    Time frame: 2 years

    Measuring weight during clinical trial

  2. Medication changes after surgery

    Time frame: 2 years

    Medication changes after surgery

  3. Concomitant cardiovascular conditions and relevant comorbidities

    Time frame: 2 years

    Medical history of patient

  4. Change in left atrial volume

    Time frame: 2 years

    Change in left atrial volume measured by transthoracic echocardiography

  5. Change in left ventricular diastolic dysfunction

    Time frame: 2 years

    Change in left ventricular diastolic dysfunction measured by transthoracic echocardiography with the definition according to the leading guidelines

  6. Change in left ventricular ejection fraction

    Time frame: 2 years

    Change in left ventricular ejection fraction measured by transthoracic echocardiography

  7. Change in right ventricular function

    Time frame: 2 years

    Change in right ventricular function measured by transthoracic echocardiography with the definition according to the leading guidelines

  8. Change in diameter of epicardial fat

    Time frame: 2 years

    Change in diameter of epicardial fat measured by transthoracic echocardiography

  9. Healthcare resource use/costs

    Time frame: 2 years

    Measured with the iMedical Consumption Questionnaire (instrument for measuring medical consumption, costs will be estimated by given answers and relation to known costs of the items of medical consumption)

  10. Health related quality of life / utility

    Time frame: 2 years

    Measured with the 5-level EQ-5D questionnaire (The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression)

Study contacts

Contact information is provided by the study sponsor or research team.

Michiel Rienstra, MD, PhD

CONTACT

[email protected]

+31503611327

Thomas M Gorter, MD, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University Medical Center Groningen

Other

Collaborators

  • Rijnstate Hospital

Registry information

Official study title

Bariatric Surgery Evaluation and Assessment of Treatment Efficacy in Heart Failure with Preserved Ejection Fraction - Intervention Trial

Acronym: BEAT-IT

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Oct 3, 2023
Registry last updated
Apr 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.